Tel. +41 61 295 50 00info@baselarea. swiss
The Basel-based pharma group Axovant has agreed a manufacturing partnership with Yposkesi. Axovant will benefit from expanded production capacities to manufacture gene therapies.
Yposkesi specializes in contract manufacturing of pharmaceutical products and complies with the regulations stipulated by both the US Food and Drug Administration and the European Medicines Agency. The partnership with Yposkesi will enable Axovant to access additional resources to manufacture gene therapies, particularly for AAV (Adeno-associated viruses)-based gene therapies, as outlined in a press release.
Pavan Cheruvo, CEO of Axovant, explained in the press release how access to additional production capacities is a key component in the continued development of drug candidates from the gene therapy program. Yposkesi is the preferred manufacturing partner as the Basel-based pharma group would benefit from reserved manufacturing capacity due to the collaboration and because Yposkesi is planning to further expand its own capacities. In this context, the French firm is seeking to double its production area from 5,000 square meters to 10,000 square meters by 2021.
Axovant, a subsidiary of Roivant Sciences, which is also based in Basel, specializes in gene therapies and their clinical development. One of the most important development candidates in its pipeline is a drug to treat Parkinson’s disease.